Zhen-Yu Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhen-Yu Yan has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Yan-Yan Xie
Department of Hematology, North China University of Science and Technology Affiliated Hospital, Tangshan, China
4 shared publicationsLe Jiang
Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
3 shared publicationsLin-Hong Wang
Department of Hematology, The Affiliated Hospital of North China University of Science and Technology, Tangshan 063000, Hebei Province, China
3 shared publications- Xin-Guang Liu
Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
3 shared publications Lisha Zhao
Department of Hematology, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, 063000, China
2 shared publicationsMei-Rong Yang
Department of Hematology, North China University of Science and Technology Affiliated Hospital, Tangshan, China
2 shared publications
Latest Publications
- 16 June 2026
- Published by Elsevier in Thrombosis Research
- Vol. 263, 109750
Postoperative thrombosis in patients with hemophilia and malignancy: Mechanisms and perioperative prevention and management — A scoping review
- 16 June 2026
- Published by Elsevier in Thrombosis Research
- Vol. 263, 109750
Postoperative thrombosis in patients with hemophilia and malignancy: Mechanisms and perioperative prevention and management — A scoping review
- Open Access
- 31 March 2026
- Published by Taylor & Francis in Platelets
- Vol. 37 (1) , 2653082
Abnormal expansion of peripheral helper T cells in primary immune thrombocytopenia
Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count (<100 × 109/L) and varying degrees of hemorrhage.1 Its pathogenesis encompasses multifaceted im...
- 31 March 2026
- Published by Taylor & Francis in Platelets
- Vol. 37 (1) , 2653082
Open AccessAbnormal expansion of peripheral helper T cells in primary immune thrombocytopenia
Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count (<100 × 109/L) and varying degrees of hemorrhage.1 Its pathogenesis encompasses multifaceted im...
- Open Access
- 17 March 2026
- Published by Elsevier in Journal of the Formosan Medical Association
Beyond association: Towards mechanistic precision in virus-associated hematologic malignancies
- 17 March 2026
- Published by Elsevier in Journal of the Formosan Medical Association
Open AccessBeyond association: Towards mechanistic precision in virus-associated hematologic malignancies
- Open Access
- 11 February 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (6) , e70176
The Genetic Link Between Primary Immune Thrombocytopenia and Depression/Anxiety Disorders: A Two‐Sample Mendelian Randomization Study
Background: Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with complex immunopathogenesis. Its major symptoms, such as bleeding tendency and fatigue, may predispose patients to depression and anxiety. Although psychiatric comorbidities are increasingly recognized in ITP management, whether ITP causally contributes to these conditions remains unclear. Methods: We conducted a two‐sample Mendelian randomization (MR) study to investigate the potential genetically causal links between ITP and depression/anxiety. To ensure robustness, complementary MR approaches were performed, including pleiotropy‐robust methods (MR‐Corr and MRMix), multivariable MR adjusting for inflammatory biomarkers (C‐reactive protein and interleukin‐6), the robust adjusted profile score (RAPS) model, reverse MR, and colocalization analysis. Results: MR analysis revealed a positive causal effect of ITP on depression (OR = 1.007, 95% CI: 1.001–1.013; p = 0.014), whereas no genetic predisposition of ITP on anxiety was observed. Multivariable and pleiotropy‐robust sensitivity analyses supported the stability and consistency of the ITP‐depression association, indicating that the result was unlikely driven by pleiotropy, instrument weakness, or inflammatory confounding. Conclusion: These findings provided novel genetic evidence supporting ITP‐associated mental health issues and highlighted the importance of integrated psycho‐hematological interventions for ITP in clinical practice. Future research was needed to elucidate the biological underpinning between ITP and psychiatric disorders, which might provide more options for ITP patients to improve life quality.
- 11 February 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (6) , e70176
Open AccessThe Genetic Link Between Primary Immune Thrombocytopenia and Depression/Anxiety Disorders: A Two‐Sample Mendelian Randomization Study
Background: Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with complex immunopathogenesis. Its major symptoms, such as bleeding tendency and fatigue, may predispose patients to depression and anxiety. Although psychiatric comorbidities are increasingly recognized in ITP management, whether ITP causally contributes to these conditions remains unclear. Methods: We conducted a two‐sample Mendelian randomization (MR) study to investigate the potential genetically causal links between ITP and depression/anxiety. To ensure robustness, complementary MR approaches were performed, including pleiotropy‐robust methods (MR‐Corr and MRMix), multivariable MR adjusting for inflammatory biomarkers (C‐reactive protein and interleukin‐6), the robust adjusted profile score (RAPS) model, reverse MR, and colocalization analysis. Results: MR analysis revealed a positive causal effect of ITP on depression (OR = 1.007, 95% CI: 1.001–1.013; p = 0.014), whereas no genetic predisposition of ITP on anxiety was observed. Multivariable and pleiotropy‐robust sensitivity analyses supported the stability and consistency of the ITP‐depression association, indicating that the result was unlikely driven by pleiotropy, instrument weakness, or inflammatory confounding. Conclusion: These findings provided novel genetic evidence supporting ITP‐associated mental health issues and highlighted the importance of integrated psycho‐hematological interventions for ITP in clinical practice. Future research was needed to elucidate the biological underpinning between ITP and psychiatric disorders, which might provide more options for ITP patients to improve life quality.
- Open Access
- 12 May 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 25 (1) , 1-9
Efficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): a multicenter, single-arm, phase III trial
A novel, highly purified 10% intravenous immunoglobulin (IVIG) formulation was evaluated for both therapeutic efficacy and safety profile in adult patients diagnosed with persistent or chronic primary immune thrombocytopenia (ITP). This phase III, multicenter, open-label, single-arm clinical trial enrolled Chinese adult patients diagnosed with persistent or chronic ITP presenting with baseline platelet counts below 30 × 109/L. Participants received intravenous administration of 10% IVIG at a standardized dosage of 1 g/kg/day for two consecutive days. The primary efficacy endpoint was defined as the proportion of subjects achieving both a platelet count elevation to ≥ 30 × 109/L and a minimum two-fold increase from baseline values within a 7-day post-treatment observation period following the first dose administration. Seventy-two patients were enrolled and sixty patients completed the study. 52 (72.2%; 95% CI: 60.4, 82.1) patients achieved platelet count ≥ 30 × 109/L and experienced a ≥ twofold increase from baseline within 7 days, and 52 (72.2%; 95% CI: 60.4, 82.1) patients achieved complete response (CR) or response (R) within 7 days. 64 patients (88.9%; 95% CI: 79.3, 95.1) achieved platelet count ≥ 50 × 109/L within 7 days with a median time of 3 days. 71 patients completed the ITP bleeding scale assessment after 7 days, showing a decrease of 0.6 ± 1.07 from baseline. A total of 66 patients (91.7%) reported treatment-emergent adverse events (TEAEs) during the study, and 37 patients (51.4%) reported adverse drug reactions (ADRs). The most prevalent ADRs with an incidence exceeding 5% included headache (n = 12, 16.7%), fever (n = 10, 13.9%), decreased white blood cell count (n = 5, 6.9%), and nausea (n = 5, 6.9%). The therapeutic regimen of 10% IVIG administered at a dosage of 1 g/kg/day for two consecutive days demonstrated both favorable safety profiles and clinical efficacy. These robust findings provide substantial evidence supporting the clinical application of this novel 10% IVIG formulation in the management of adult patients with ITP.
- 12 May 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 25 (1) , 1-9
Open AccessEfficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): a multicenter, single-arm, phase III trial
A novel, highly purified 10% intravenous immunoglobulin (IVIG) formulation was evaluated for both therapeutic efficacy and safety profile in adult patients diagnosed with persistent or chronic primary immune thrombocytopenia (ITP). This phase III, multicenter, open-label, single-arm clinical trial enrolled Chinese adult patients diagnosed with persistent or chronic ITP presenting with baseline platelet counts below 30 × 109/L. Participants received intravenous administration of 10% IVIG at a standardized dosage of 1 g/kg/day for two consecutive days. The primary efficacy endpoint was defined as the proportion of subjects achieving both a platelet count elevation to ≥ 30 × 109/L and a minimum two-fold increase from baseline values within a 7-day post-treatment observation period following the first dose administration. Seventy-two patients were enrolled and sixty patients completed the study. 52 (72.2%; 95% CI: 60.4, 82.1) patients achieved platelet count ≥ 30 × 109/L and experienced a ≥ twofold increase from baseline within 7 days, and 52 (72.2%; 95% CI: 60.4, 82.1) patients achieved complete response (CR) or response (R) within 7 days. 64 patients (88.9%; 95% CI: 79.3, 95.1) achieved platelet count ≥ 50 × 109/L within 7 days with a median time of 3 days. 71 patients completed the ITP bleeding scale assessment after 7 days, showing a decrease of 0.6 ± 1.07 from baseline. A total of 66 patients (91.7%) reported treatment-emergent adverse events (TEAEs) during the study, and 37 patients (51.4%) reported adverse drug reactions (ADRs). The most prevalent ADRs with an incidence exceeding 5% included headache (n = 12, 16.7%), fever (n = 10, 13.9%), decreased white blood cell count (n = 5, 6.9%), and nausea (n = 5, 6.9%). The therapeutic regimen of 10% IVIG administered at a dosage of 1 g/kg/day for two consecutive days demonstrated both favorable safety profiles and clinical efficacy. These robust findings provide substantial evidence supporting the clinical application of this novel 10% IVIG formulation in the management of adult patients with ITP.
- 1 October 2020
- Vol. 28 (5) , 1718-1725
[Expression of Adenovirus-mediated Human Clotting Factor IX Gene in Mouse Adipose-derived Stem Cells].
To investigate the adenovirus-mediated expression of human clotting factor IX (hFIX) gene in mouse adipose-derived stem cells(ADSC). The mouse ADSC were isolated and cultured in vitro, the morphology of cells was observed and its growth viability was detected by using CCK-8. Cell surface markers CD29,CD90,CD45 were identified by flow cytometry, and its diferentiation ability was identified by adipogenic and osteogenic induction. Morphological changes was observed and the growth curve should be drawn after transfecting ADSC with adenovirus containing hFIX gene. The expression of hFIX gene was detected by RT-PCR. The expression of hFIX protein in ADSC or in culture supernatant was detected by Western blot. hFIX protein in the supernatant was measured by ELISA, and the clotting factor activity of hFIX in culture supernatant was measured by one-stage method. The in vitro cultured mouse ADSC displayed microspherical shape and strong refractive property. Anchoring growth was lasted for 4-6 hours after planting into culture flask. After cultured for 72 hours, the cells showed long spindle-shaped fibrous and swirling arrangement. The overall growth trend of the third generation ADSC cultured in vitro was S-shaped. The formation of lipid droplets could be observed in the induced cells with Oil red O staining by inverted microscope. After alizarin red staining, the orange-red calcified bone nodes were observed in the induced cells under inverted phase contrast microscope. CD29 (99.91%) and CD90 (99.02%) highly expressed in the third generation of ADSC, but CD45 (0.94%) almost not expressed. RT-PCR showed the hFIX gene could expressed in mouse ADSC. Western blot showed that hFIX protein expressed in both ADSC and culture supernatant. FIX:Ag in cell supernatant was 21.33±3.93 ng/(106 cells.24 h) on the first day, 12.63±0.86 ng/(106 cells.24 h) on the third day and 12.63±2.36 ng/(106 cells.24 h) on the ninth day. FIX:C in culture supernatant was 8.5%. Adenovirus-carried hFIX gene can effectively transfect ADSC. ADSC modified by hFIX gene can secrete hFIX protein with coagulation activity.
- 1 October 2020
- Vol. 28 (5) , 1718-1725
[Expression of Adenovirus-mediated Human Clotting Factor IX Gene in Mouse Adipose-derived Stem Cells].
To investigate the adenovirus-mediated expression of human clotting factor IX (hFIX) gene in mouse adipose-derived stem cells(ADSC). The mouse ADSC were isolated and cultured in vitro, the morphology of cells was observed and its growth viability was detected by using CCK-8. Cell surface markers CD29,CD90,CD45 were identified by flow cytometry, and its diferentiation ability was identified by adipogenic and osteogenic induction. Morphological changes was observed and the growth curve should be drawn after transfecting ADSC with adenovirus containing hFIX gene. The expression of hFIX gene was detected by RT-PCR. The expression of hFIX protein in ADSC or in culture supernatant was detected by Western blot. hFIX protein in the supernatant was measured by ELISA, and the clotting factor activity of hFIX in culture supernatant was measured by one-stage method. The in vitro cultured mouse ADSC displayed microspherical shape and strong refractive property. Anchoring growth was lasted for 4-6 hours after planting into culture flask. After cultured for 72 hours, the cells showed long spindle-shaped fibrous and swirling arrangement. The overall growth trend of the third generation ADSC cultured in vitro was S-shaped. The formation of lipid droplets could be observed in the induced cells with Oil red O staining by inverted microscope. After alizarin red staining, the orange-red calcified bone nodes were observed in the induced cells under inverted phase contrast microscope. CD29 (99.91%) and CD90 (99.02%) highly expressed in the third generation of ADSC, but CD45 (0.94%) almost not expressed. RT-PCR showed the hFIX gene could expressed in mouse ADSC. Western blot showed that hFIX protein expressed in both ADSC and culture supernatant. FIX:Ag in cell supernatant was 21.33±3.93 ng/(106 cells.24 h) on the first day, 12.63±0.86 ng/(106 cells.24 h) on the third day and 12.63±2.36 ng/(106 cells.24 h) on the ninth day. FIX:C in culture supernatant was 8.5%. Adenovirus-carried hFIX gene can effectively transfect ADSC. ADSC modified by hFIX gene can secrete hFIX protein with coagulation activity.
- 1 June 2020
- Vol. 28 (3) , 948-955
[Adenovirus-mediated Expression of B-domain-Deleted Human Coagulation Factor Ⅷ in ADSC of SD Rats].
To transinfect SD adipose tissue-derived stem cell (ADSC) in vitro with a recombinant adenoviral vector containing human B-domain-deleted FVIII (BDDhFⅧ), so as to lay the foundation for the treatment of hemophilia A by using ADSC combined with BDDhFⅧ gene. ADSCs were isolated from the inguinal adipose tissue of SD rats and passed to third passage for identification. Third passage ADSCs were transfected in vitro with recombinant adenovirus vector Ad-BDDhFⅧ-GFP. The experiments were divided into Ad-BDDhFⅧ-GFP-transfected ADSCs group (A), Ad-GFP-transfected ADSC group (B), and untransfected ADSC group (C). CCK-8 method was used to detect the proliferation of transfected cells in three groups, and the expression level of hFⅧ antigen in cell supernatant was detected by ELISA. RT-PCR and Western blot respectively were used to detect the mRNA and protein expression of BDDhFⅧ in the three groups after transfection. The growth curve of third passage cells isolated and cultured showed an inverted "S" shap; the flow cytometry detection showed the positive expression of CD29, CD90, CD44, and the negative expression of CD45 in third passage cells. After the adipogenic and osteogenic induction, the cells could transformed to adipogenic and osteogenic directions. CCK-8 detection showed that the proliferation of cells in 3 groups not was influenced. ELISA showed that the expression of hFⅧAg in group A was significantly higher than that in group B and C (P<0.05). RT-PCR showed that compared with group A, there was no target band in B and C groups, and BDDhFⅧ gene was not expressed. The results in group A were consistent with the length of amplified fragments, and BDDhFⅧ target gene was expressed. Western blot analysis showed that the expression of hFⅧ protein in group A was significantly higher than that in group B and C. (P<0.05). Recombinant adenovirus Ad-BDDhFⅧ-GFP can effectively transfect rat ADSC in vitro, which lays an experimental foundation for gene therapy of hemophilia A.
- 1 June 2020
- Vol. 28 (3) , 948-955
[Adenovirus-mediated Expression of B-domain-Deleted Human Coagulation Factor Ⅷ in ADSC of SD Rats].
To transinfect SD adipose tissue-derived stem cell (ADSC) in vitro with a recombinant adenoviral vector containing human B-domain-deleted FVIII (BDDhFⅧ), so as to lay the foundation for the treatment of hemophilia A by using ADSC combined with BDDhFⅧ gene. ADSCs were isolated from the inguinal adipose tissue of SD rats and passed to third passage for identification. Third passage ADSCs were transfected in vitro with recombinant adenovirus vector Ad-BDDhFⅧ-GFP. The experiments were divided into Ad-BDDhFⅧ-GFP-transfected ADSCs group (A), Ad-GFP-transfected ADSC group (B), and untransfected ADSC group (C). CCK-8 method was used to detect the proliferation of transfected cells in three groups, and the expression level of hFⅧ antigen in cell supernatant was detected by ELISA. RT-PCR and Western blot respectively were used to detect the mRNA and protein expression of BDDhFⅧ in the three groups after transfection. The growth curve of third passage cells isolated and cultured showed an inverted "S" shap; the flow cytometry detection showed the positive expression of CD29, CD90, CD44, and the negative expression of CD45 in third passage cells. After the adipogenic and osteogenic induction, the cells could transformed to adipogenic and osteogenic directions. CCK-8 detection showed that the proliferation of cells in 3 groups not was influenced. ELISA showed that the expression of hFⅧAg in group A was significantly higher than that in group B and C (P<0.05). RT-PCR showed that compared with group A, there was no target band in B and C groups, and BDDhFⅧ gene was not expressed. The results in group A were consistent with the length of amplified fragments, and BDDhFⅧ target gene was expressed. Western blot analysis showed that the expression of hFⅧ protein in group A was significantly higher than that in group B and C. (P<0.05). Recombinant adenovirus Ad-BDDhFⅧ-GFP can effectively transfect rat ADSC in vitro, which lays an experimental foundation for gene therapy of hemophilia A.
- 1 June 2016
- Vol. 24 (3) , 810-4
[A Preliminary Exploration on the Pathogenesis of Osteopenia in Patients with Hemophilia].
To investigate the influencing factors and pathogenesis of osteopenia in the patients with hemophilia. Twenty-three patients with hemophilia were admitted in the hospital affiliated to North China University of Science and technology from March to August 2015, including 13 severe cases, 10 mild and moderate cases. All the patients accepted the detection of serum I collagen cross-linking N terminal peptide (NTX I), osteoprotegerin (OPG), bone alkaline phosphatase (BALP), basic fibroblast growth factor (bFGF), insulin-like growth factor (IGF) and transforming growth factor-β1 (TGF-β1), the score scale of activity ability was recorded according to the criteria published by the U.S. Center for disease prevention and control in 2002, and 21 patients received the measurement of bone mineral density. According to the World Health Organization (WHO) definition, the clinical significance of bone mineral density (BMD) was assessed by measuring the Z level. Z level>-2 was recorded in 10 cases, Z≤-2 was recorded in 11 cases; the levels of body mass index (BMI) and human bone alkaline phosphatase (BALP) reflecting bone formation in 11 cases (Z≤-2) were lower than there in 10 cases (Z>-2) (P0.05). The BMD level does not correlate with the clinial grouping of hemophilia, the low body mass index may be a risk factor for bone lose; the mechanism of hemophilia patient's bone lose may be related with the decrease of osteogenic activity, the IGF can prevent bone lose in hemophilia, the bFGF and OPG can promote bone metabolism of the patients with hemophilia.
- 1 June 2016
- Vol. 24 (3) , 810-4
[A Preliminary Exploration on the Pathogenesis of Osteopenia in Patients with Hemophilia].
To investigate the influencing factors and pathogenesis of osteopenia in the patients with hemophilia. Twenty-three patients with hemophilia were admitted in the hospital affiliated to North China University of Science and technology from March to August 2015, including 13 severe cases, 10 mild and moderate cases. All the patients accepted the detection of serum I collagen cross-linking N terminal peptide (NTX I), osteoprotegerin (OPG), bone alkaline phosphatase (BALP), basic fibroblast growth factor (bFGF), insulin-like growth factor (IGF) and transforming growth factor-β1 (TGF-β1), the score scale of activity ability was recorded according to the criteria published by the U.S. Center for disease prevention and control in 2002, and 21 patients received the measurement of bone mineral density. According to the World Health Organization (WHO) definition, the clinical significance of bone mineral density (BMD) was assessed by measuring the Z level. Z level>-2 was recorded in 10 cases, Z≤-2 was recorded in 11 cases; the levels of body mass index (BMI) and human bone alkaline phosphatase (BALP) reflecting bone formation in 11 cases (Z≤-2) were lower than there in 10 cases (Z>-2) (P0.05). The BMD level does not correlate with the clinial grouping of hemophilia, the low body mass index may be a risk factor for bone lose; the mechanism of hemophilia patient's bone lose may be related with the decrease of osteogenic activity, the IGF can prevent bone lose in hemophilia, the bFGF and OPG can promote bone metabolism of the patients with hemophilia.